MTST

MetaStat Inc

MTST, USA

MetaStat, Inc., a precision medicine company, focuses on discovering and developing therapeutic and diagnostic treatment solutions for cancer patients. The company is developing novel drug candidates and companion diagnostic tests that target the MENA pathway. Its product candidates include MENA diagnostic assay, a tissue-based quantitative immunofluorescence test that measures expression of the pro-metastatic MENA protein splice-variant; companion diagnostic to predict RTK inhibitor drug responses and anti-microtubule drug responses; liquid blood-based biopsy to enhance cancer diagnosis and optimize patient care; MetaSite Breast assay, an immunohistochemistry test that measures micro-anatomical intravasat at blood vessels within the tumor microenvironment ion sites; and prognostic diagnostic to predict risk of cancer metastasis. The company's therapeutic targets a critical metastatic pathway in solid tumors responsible for driving tumor resistance and the spread of aggressive cancer. MetaStat, Inc. is based in Boston, Massachusetts.

https://www.metastat.com

Stock Price

$0.00

0%

decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
MTST
stock
MTST

Hiking Mt. St. Helens, 41 Years After the Blast Backpacker Magazine

Read more →
MTST
stock
MTST

Embracing Mother Earth at Mt. St. Francis Retreat cochraneeagle.ca

Read more →

Showing 2 of 5

Finn Analysis

(Last Updated 2018-02-28)

Health Score

Price to Book Ratio (P/B)

-

Very Low

-0.00

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very High

62.75 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-133.22 %

Low ≤ 2%

High ≥ 10%

Investors

* Institutions hold a combined 0.00% of the total shares of MetaStat Inc

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2024-11-30

EPS Actual

0

EPS Estimate

0

EPS Difference

0

Surprise Percent

0%

Investing Fit Scorecard

(Last Updated 2018-02-28)

Deep Value
Weak Deep Value(2)
Defensive
Moderately Defensive(5.5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(5.3)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(2)
Momentum
Moderate Momentum(3.5)
Net Net
Not Undervalued (Net-Net)(2)
Quality
Low Quality Business(2.5)
Value
Overpriced(2.5)

Income Statement

(Last Updated 2018-02-28)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2018-02-28)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2018-02-28)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.